TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39361218

Group type: EXPERIMENTAL
Intervention: Radium-223 therapy
Number of subjects: 55
Study: 39361227

Group type: EXPERIMENTAL
Intervention: Web-based weight loss intervention over 24 weeks
Number of subjects: 112

Group type: COMPARATOR
Intervention: Cohabitating dyads
Number of subjects: 112

Group type: COMPARATOR
Intervention: Non-cohabitating dyads
Number of subjects: 112
Study: 39361293

Group type: EXPERIMENTAL
Intervention: Mouth closure during sleep by applying pressure to the mentum until teeth are in occlusion
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mouth closure in patients with near-zero mouth breathing
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mouth closure in patients with moderate levels of mouth breathing
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Mouth closure in patients with high levels of mouth breathing
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Velopharyngeal obstruction
Number of subjects: 54
Study: 39361311

Group type: EXPERIMENTAL
Intervention: ATP plus shock
Number of subjects: 2595

Group type: COMPARATOR
Intervention: Shock only
Number of subjects: 2595
Study: 39361572

Group type: EXPERIMENTAL
Intervention: Cardiac prehabilitation/rehabilitation/education (CREED AF) intervention
Number of subjects: 106

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 106
Study: 39361597

Group type: EXPERIMENTAL
Intervention: JanaCare Aina Blood Monitoring System (JCAina)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tascom SimplexTAS 101 device (TAS101)
Number of subjects: 0
Study: 39361705

Group type: EXPERIMENTAL
Intervention: Clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vehicle gel
Number of subjects: 0
Study: 39361914

Group type: EXPERIMENTAL
Intervention: Countermarketing messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Health education messages
Number of subjects: 0
Study: 39361946

Group type: COMPARATOR
Intervention: Standard-of-care chemotherapy (SOC) - once weekly paclitaxel, topotecan, or pegylated liposomal doxorubicin
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Cediranib/olaparib
Number of subjects: 562

Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 562
Study: 39362046

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK) at 5 μg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK) at 15 μg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK) at 25 μg/kg
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Denileukin diftitox (ONTAK)
Number of subjects: 10
Study: 39362248

Group type: EXPERIMENTAL
Intervention: Ziftomenib (50-1000 mg) orally once daily in 28-day cycles (Phase 1a)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Ziftomenib (600 mg) in Phase 1b
Number of subjects: 83

Group type: COMPARATOR
Intervention: Ziftomenib (200 mg) in Phase 1b
Number of subjects: 83
Study: 39362249

Group type: EXPERIMENTAL
Intervention: Capmatinib (400 mg orally twice daily)
Number of subjects: 373
Study: 39362630

Group type: EXPERIMENTAL
Intervention: Coaching intervention (≤6 live virtual coaching sessions)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Coaching intervention (WHO Wellbeing Index (WHO-5))
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Coaching intervention (Perceived Stress Scale (PSS))
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Coaching intervention (Utrecht Work Engagement Scale (UWES))
Number of subjects: 28
Study: 39362749

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA)
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Visual inspection with acetic acid (VIA) with iodine
Number of subjects: 878

Group type: COMPARATOR
Intervention: Visual inspection without iodine
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: Visual inspection with iodine
Number of subjects: 878

Group type: EXPERIMENTAL
Intervention: HIV positive status
Number of subjects: 878
Study: 39362795

Group type: EXPERIMENTAL
Intervention: Formula milk and feeding accessories
Number of subjects: 419

Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding (BF)
Number of subjects: 419

Group type: COMPARATOR
Intervention: Non-breastfeeding (non-BF) mothers' diet
Number of subjects: 419
Study: 39362907

Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD) administered from 180 to 195 minutes
Number of subjects: 15
Study: 39362933

Group type: EXPERIMENTAL
Intervention: Sirukumab
Number of subjects: 209

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study: 39363095

Group type: EXPERIMENTAL
Intervention: Testosterone therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin plus testosterone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39363100

Group type: EXPERIMENTAL
Intervention: Doxycycline post-exposure prophylaxis (200-mg dose taken after condomless sex)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 150
Study: 39363201

Group type: EXPERIMENTAL
Intervention: Macrolides (azithromycin) for 5 days
Number of subjects: 376

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 376
Study: 39363230

Group type: EXPERIMENTAL
Intervention: Moderate hypoxia with cognitive training
Number of subjects: 180

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 180
Study: 39363243

Group type: EXPERIMENTAL
Intervention: Givosiran
Number of subjects: 16
Study: 39363246

Group type: EXPERIMENTAL
Intervention: Penicillin allergy assessment pathway
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual clinical care
Number of subjects: 0
Study: 39363320

Group type: EXPERIMENTAL
Intervention: Targeted therapy
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Tailored treatment based on resistance mechanism
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Patient-derived xenografts (PDX)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: PDX models for various cancers
Number of subjects: 857
Study: 39363376

Group type: EXPERIMENTAL
Intervention: 4-week aerobic exercise training program (12 supervised sessions on a cycling ergometer)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Attention control group
Number of subjects: 24
Study: 39363383

Group type: EXPERIMENTAL
Intervention: TranS-C + MSI
Number of subjects: 178

Group type: COMPARATOR
Intervention: TranS-C alone
Number of subjects: 178
Study: 39363801

Group type: EXPERIMENTAL
Intervention: Allergen Immunotherapy (AIT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of AIT and biologics
Number of subjects: 0
Study: 39364270

Group type: EXPERIMENTAL
Intervention: NACRT (n=25)
Number of subjects: 45

Group type: COMPARATOR
Intervention: NACT (control, n=20)
Number of subjects: 45
Study: 39364271

Group type: EXPERIMENTAL
Intervention: Infected volunteers (n=18)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Uninfected volunteers (n=16)
Number of subjects: 34
Study: 39364754

Group type: EXPERIMENTAL
Intervention: Eye-tracking training for 20 sessions over 9 months
Number of subjects: 40

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 40
Study: 39364857

Group type: EXPERIMENTAL
Intervention: Periodic Resistance Training (PRT)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Continuous Resistance Training (CRT)
Number of subjects: 55
Study: 39364876

Group type: EXPERIMENTAL
Intervention: Gallstone disease
Number of subjects: 3480
Study: 39364940

Group type: EXPERIMENTAL
Intervention: GnRH agonist (GnRHa) therapy
Number of subjects: 814
Study: 39365190

Group type: EXPERIMENTAL
Intervention: High-concentration (4.5%) HA-based filler with hybrid cooperative complexes (HCC)
Number of subjects: 28
Study: 39365383

Group type: EXPERIMENTAL
Intervention: Lower Assist Maneuver (LAM) during Neurally Adjusted Ventilatory Assist (NAVA) and Neural Pressure Support (NPS)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Lower Assist Maneuver (LAM)
Number of subjects: 10
Study: 39365384

Group type: EXPERIMENTAL
Intervention: Embolization
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Splenectomy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Surveillance
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: OIS grade 4 or 5 splenic trauma
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Arterial leak
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pseudoaneurysm
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Pseudocyst
Number of subjects: 140
Study: 39365658

Group type: EXPERIMENTAL
Intervention: I-InTERACT-North web-based stepped-care parent support program
Number of subjects: 244

Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 244
Study: 39365895

Group type: EXPERIMENTAL
Intervention: Intact fish skin graft
Number of subjects: 255

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 255
Study: 39365957

Group type: EXPERIMENTAL
Intervention: FDG-PET-guided adaptive treatment (mean 71 Gy in 30 fractions, mean lung dose 17.9 Gy)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Standard treatment (60 Gy/30 fractions)
Number of subjects: 127
Study: 39365960

Group type: EXPERIMENTAL
Intervention: Glofitamab monotherapy with obinutuzumab pretreatment (Gpt) 1,000 or 2,000 mg 7 days before glofitamab; glofitamab step-up dosing on days 8 (2.5 mg) and 15 (10 mg) of cycle 1, target dose of 16 or 30 mg once every 3 weeks from cycle 2 day 1 onward, for 12 cycles.
Number of subjects: 61
Study: 39365990

Group type: EXPERIMENTAL
Intervention: Personalized Training (PT)
Number of subjects: 112

Group type: COMPARATOR
Intervention: Free Training (FT)
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Both groups together
Number of subjects: 112
Study: 39365992

Group type: EXPERIMENTAL
Intervention: Ruxolitinib 10mg twice daily for up to 12 cycles
Number of subjects: 49
Study: 39366004

Group type: EXPERIMENTAL
Intervention: Reduced carbohydrate diet (RCHO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 39366028

Group type: EXPERIMENTAL
Intervention: One of the three dietary patterns of the US Dietary Guidelines
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Another dietary pattern of the US Dietary Guidelines
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: The third dietary pattern of the US Dietary Guidelines
Number of subjects: 63

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 63
Study: 39366276

Group type: EXPERIMENTAL
Intervention: Larger particle size oat flour
Number of subjects: 20

Group type: COMPARATOR
Intervention: Finely milled oat flour (control)
Number of subjects: 20
Study: 39366468

Group type: EXPERIMENTAL
Intervention: CP101
Number of subjects: 198

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 198
Study: 39366653

Group type: EXPERIMENTAL
Intervention: Bilateral sphenopalatine ganglion block (SPGB) with 5 mL lidocaine 2% on each side (G1)
Number of subjects: 120

Group type: COMPARATOR
Intervention: General anesthesia and bilateral saline injection of 5 mL on each side (G2)
Number of subjects: 120
Study: 39366722

Group type: EXPERIMENTAL
Intervention: Oral methotrexate (MTX) initiated and increased to maximum tolerated dose by week 12
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Continued MTX dose with subcutaneous adalimumab
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Higher MTX-PGs concentration
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Total MTX-PGs concentration
Number of subjects: 300
Study: 39366745

Group type: EXPERIMENTAL
Intervention: Intervention group (antenatal care)
Number of subjects: 500

Group type: COMPARATOR
Intervention: Standard-of-care group
Number of subjects: 500
Study: 39366751

Group type: EXPERIMENTAL
Intervention: Niraparib monotherapy
Number of subjects: 0
Study: 39366752

Group type: EXPERIMENTAL
Intervention: HBM4003 0.3 mg/kg plus toripalimab 240 mg every 3 weeks
Number of subjects: 40
Study: 39367057

Group type: EXPERIMENTAL
Intervention: Resting-state functional magnetic resonance imaging (rsfMRI) assessment
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: Dimensional analyses
Number of subjects: 544
Study: 39367230

Group type: EXPERIMENTAL
Intervention: Intermittent oro-esophageal tube feeding (IOE)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Nasogastric tube feeding (NGT)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: IOE
Number of subjects: 82

Group type: COMPARATOR
Intervention: NGT
Number of subjects: 82
Study: 39367366

Group type: EXPERIMENTAL
Intervention: ASSIP (Attempted Suicide Short Intervention Program) plus treatment as usual
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study: 39367394

Group type: EXPERIMENTAL
Intervention: Milled Co-Cr bar
Number of subjects: 20

Group type: COMPARATOR
Intervention: Selective laser melted (SLM) Co-Cr bar
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study: 39367399

Group type: EXPERIMENTAL
Intervention: SMART subgroup (silver modified atraumatic restorative technique)
Number of subjects: 28

Group type: COMPARATOR
Intervention: CONV subgroup (high viscosity glass ionomer restoration and fluoride varnish application)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: SMART subgroup
Number of subjects: 28

Group type: COMPARATOR
Intervention: CONV subgroup
Number of subjects: 28
Study: 39367427

Group type: EXPERIMENTAL
Intervention: TauroPace™ (TP)
Number of subjects: 1170
Study: 39367439

Group type: EXPERIMENTAL
Intervention: Telehealth intervention using videoconferencing technology for linking incarcerated women to community MOUD treatment.
Number of subjects: 0
Study: 39367450

Group type: EXPERIMENTAL
Intervention: CHV-NEO messaging integrated into eCHIS
Number of subjects: 7200

Group type: COMPARATOR
Intervention: Standard of care using eCHIS without CHV-NEO
Number of subjects: 7200

Group type: EXPERIMENTAL
Intervention: CHV-NEO messaging
Number of subjects: 7200
Study: 39367452

Group type: EXPERIMENTAL
Intervention: Lung and diaphragm protective ventilation
Number of subjects: 222

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 222
Study: 39367488

Group type: EXPERIMENTAL
Intervention: Parental questionnaires measuring developmental levels in language and social-emotional domains, parental mental well-being, life events, parenting stress, parenting styles, and family relationships.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Behavioral assessments using Griffiths Development Scales and Wechsler Preschool and Primary Scale of Intelligence.
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Behavior observation experiments targeting behavioral inhibition, compliance, self-control, and social-emotional regulation.
Number of subjects: 1000
Study: 39367749

Group type: EXPERIMENTAL
Intervention: Handgrip strength (HGS) measured using a hand dynamometer.
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Impulse oscillometry for evaluating SAD, defined as R5-R20 ⩾0.07 kPa/L/s.
Number of subjects: 64
Study: 39368033

Group type: EXPERIMENTAL
Intervention: Sigh breaths during pressure support ventilation (PSV)
Number of subjects: 56

Group type: COMPARATOR
Intervention: No Sigh during pressure support ventilation (PSV)
Number of subjects: 56
Study: 39368039

Group type: EXPERIMENTAL
Intervention: Tucatinib (300 mg twice daily)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Healthy participants (control group)
Number of subjects: 283
Study: 39368068

Group type: COMPARATOR
Intervention: Hypertensive group
Number of subjects: 1055
Study: 39368130

Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by concerns and misinformation surrounding the new vaccine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by witnessing others' vaccine and pandemic experiences.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by participation in social activities.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by the politicization of and political climate surrounding the vaccine.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pediatric COVID-19 vaccine uptake influenced by health education surrounding the vaccines.
Number of subjects: 0
Study: 39368335

Group type: EXPERIMENTAL
Intervention: Gentle Hatha and Restorative Yoga, performed two to three times per week for four weeks at a low to moderate level of intensity.
Number of subjects: 177
Study: 39368459

Group type: EXPERIMENTAL
Intervention: iCBT-Email
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: iCBT-Video
Number of subjects: 57
Study: 39368474

Group type: EXPERIMENTAL
Intervention: Ustekinumab
Number of subjects: 0
Study: 39368488

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec (icodec) with a dosing guide app
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Once-weekly insulin icodec (icodec)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Once-daily basal insulin
Number of subjects: 0
Study: 39368797

Group type: EXPERIMENTAL
Intervention: Not applicable (observational study)
Number of subjects: 807
Study: 39368841

Group type: EXPERIMENTAL
Intervention: Sepiapterin
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 39368870

Group type: EXPERIMENTAL
Intervention: Emotional competence app
Number of subjects: 2532

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) app
Number of subjects: 2532

Group type: EXPERIMENTAL
Intervention: Self-monitoring app
Number of subjects: 2532

Group type: COMPARATOR
Intervention: All groups (emotional competence app, CBT app, self-monitoring app)
Number of subjects: 2532
Study: 39368871

Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT) self-help app
Number of subjects: 1262

Group type: EXPERIMENTAL
Intervention: Emotional competence self-help app
Number of subjects: 1262

Group type: COMPARATOR
Intervention: Self-monitoring app
Number of subjects: 1262
Study: 39368878

Group type: EXPERIMENTAL
Intervention: Venetoclax in combination with high-dose cytarabine (HDAC)
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Venetoclax 400 mg adult-equivalent
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Venetoclax
Number of subjects: 121
Study: 39368973

Group type: EXPERIMENTAL
Intervention: Neoadjuvant fulvestrant with enzalutamide (Combo)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Neoadjuvant fulvestrant (Fulv)
Number of subjects: 59
Study: 39369129

Group type: EXPERIMENTAL
Intervention: Time-to-therapy > 2 years
Number of subjects: 1627

Group type: EXPERIMENTAL
Intervention: Time-to-therapy > 2 years in low-risk subgroup
Number of subjects: 1627
Study: 39369231

Group type: EXPERIMENTAL
Intervention: Proton radiotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: X-ray radiotherapy
Number of subjects: 40
Study: 39369239

Group type: EXPERIMENTAL
Intervention: Five-session telephone-delivered behavioural activation treatment as an add-on to treatment as usual
Number of subjects: 250

Group type: COMPARATOR
Intervention: Treatment as usual in primary care
Number of subjects: 250
Study: 39369249

Group type: EXPERIMENTAL
Intervention: Inhalation induction
Number of subjects: 326

Group type: COMPARATOR
Intervention: Intravenous induction
Number of subjects: 326
Study: 39369275

Group type: EXPERIMENTAL
Intervention: Higher dietary quality (measured by AHEI-2010)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Consumption of red and processed meat
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Consumption of sugar-sweetened beverages
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Vegetable consumption
Number of subjects: 132
Study: 39369582

Group type: EXPERIMENTAL
Intervention: Pharmacological ascorbate (P-AscH)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard of care (SOC) with gemcitabine and nab-paclitaxel
Number of subjects: 0
Study: 39369790

Group type: EXPERIMENTAL
Intervention: Nivolumab plus ipilimumab with or without chemotherapy
Number of subjects: 637

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 637
Study: 39369987

Group type: EXPERIMENTAL
Intervention: Preoperative lung ultrasound score (LUS) ≥8
Number of subjects: 877

Group type: COMPARATOR
Intervention: Revised Cardiac Risk Index (RCRI) scores
Number of subjects: 877

Group type: COMPARATOR
Intervention: National Surgical Quality Improvement Program Myocardial infarction and Cardiac arrest (NSQIP-MICA) scores
Number of subjects: 877

Group type: COMPARATOR
Intervention: American Society of Anesthesiologists Physical Status (ASA-PS) classes
Number of subjects: 877

Group type: EXPERIMENTAL
Intervention: Preoperative lung ultrasound score (LUS)
Number of subjects: 877
Study: 39370144

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) 50/200/25 mg for 48 weeks
Number of subjects: 10
Study: 39370775

Group type: EXPERIMENTAL
Intervention: Bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF)
Number of subjects: 489
Study: 39370868

Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 1 (RM1) - n=66
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 2 (RM2) - n=84
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 3 (RM3) - n=64
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 4 (RM4) - n=188
Number of subjects: 519

Group type: EXPERIMENTAL
Intervention: Refined Male Cluster 5 (RM5) - n=119
Number of subjects: 519
Study: 39371020

Group type: EXPERIMENTAL
Intervention: Low-voltage area ablation (group A)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Cryoballoon-guided left atrial appendage isolation (group B)
Number of subjects: 161
Study: 39371104

Group type: EXPERIMENTAL
Intervention: Anlotinib plus penpulimab
Number of subjects: 21
Study: 39371161

Group type: EXPERIMENTAL
Intervention: Graph-based clustering approach to identify temporal segments of speech production from ECoG signals
Number of subjects: 1

Group type: EXPERIMENTAL
Intervention: Voice activity detection (VAD) model trained using ECoG signals
Number of subjects: 1

Group type: COMPARATOR
Intervention: Comparison to previous solutions trained with ground truth acoustic voice recordings
Number of subjects: 1
Study: 39371165

Group type: EXPERIMENTAL
Intervention: 25 g daily of KE (bis-octanoyl (R)-1,3-butanediol)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Taste, appearance, and calorie-matched placebo (PLA) containing canola oil
Number of subjects: 30
Study: 39371411

Group type: EXPERIMENTAL
Intervention: MOTIFS training model
Number of subjects: 42

Group type: COMPARATOR
Intervention: Care-as-Usual training
Number of subjects: 42
Study: 39372262

Group type: EXPERIMENTAL
Intervention: Topical vitamin D (cholecalciferol 50 mcg)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 64